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We present a serological assay for the specific detec-
tion of IgM and IgG antibodies against the emerg-
ing human coronavirus hCoV-EMC and the SARS-CoV 
based on protein microarray technology. The assay 
uses the S1 receptor-binding subunit of the spike 
protein of hCoV-EMC and SARS-CoV as antigens. The 
assay has been validated extensively using putative 
cross-reacting sera of patient cohorts exposed to 
the four common hCoVs and sera from convalescent 
patients infected with hCoV-EMC or SARS-CoV.
Background 
In 2012, a novel human betacoronavirus (hCoV-EMC) 
emerged in the Middle East [1]. At the end of March 
2013, 17 confirmed cases of hCoV-EMC infection had 
been reported to the World Health Organization (WHO) 
[2,3]. Person-to-person transmission had been reported 
twice by the United Kingdom (UK) and may also have 
occurred in two family clusters in Saudi Arabia (SA) 
and a hospital cluster in Jordan [2-4]. Fifteen confirmed 
cases have presented with severe acute respiratory 
infection (SARI), in some cases accompanied by acute 
renal failure [5-7]. Eleven patients have died [3]. One 
confirmed contact case in the UK and one confirmed 
case in SA presented with mild illness, and the clinical 
manifestations also appeared milder in unconfirmed 
but probable cases in the hospital cluster in Jordan 
[2-4,8]. It is important to understand the full spectrum 
of illness associated with this new human infection, 
and to determine how that relates to infectivity and the 
ability to transmit the virus, as well as to outcomes of 
diagnostic tests. 
The emergence of this novel hCoV lead to an interna-
tional collaborative laboratory response resulting in 
the rapid availability of diagnostic real-time reverse 
transcription polymerase chain reaction (RT-PCR) 
assays [9-11]. Successful use of PCR-based diagnostics 
relies on timing and technique of sampling, with knowl-
edge about kinetics of viraemia and shedding of virus 
during the course of infection. Investigations into epi-
demiologically linked clinical cases in SA and Jordan 
demonstrated that not in all symptomatic patients 
within a cluster viral RNA could be detected by RT-PCR, 
similar to what has been described for SARS and other 
infectious diseases [2,11]. For diagnosis of hCoV-EMC 
infection, virus detection by RT-PCR during the acute 
phase may be less sensitive, as samples from the 
lower respiratory tracts (tracheal aspirates, bronchoal-
veolar lavage) are necessary for optimal detection, and 
these are not as readily available as upper respiratory 
tract samples [1,6,12]. Therefore, serological testing 
is imperative to complement RT-PCR findings for ade-
quate diagnosis.  In addition serology is essential for 
the monitoring of the evolution of an outbreak, includ-
ing (retrospective) studies of asymptomatic and mild 
cases and identification of animal reservoirs. [13-16]. 
Currently an immunofluorescence assay (IFA) using 
hCoV-EMC-infected cells is available [10]. However, as 
the authors caution, this assay may generate false-
positive results due to the global co-circulation of four 
hCoVs namely hCoV-NL63, hCoV-OC43, hCoV-229E and 
hCoV-HKU1. Cross-reactivity to conserved viral pro-
teins limits the use of such whole virus-based IFAs, 
especially as antibodies against coronaviruses within 
a genus are generally known to cross-react [2,17]. 
Therefore, the European Centre for Disease Prevention 
and Control (ECDC) advised not to screen patients 
by whole virus IFA unless second stage serology is 
conducted [2]. For confirmation, virus neutralisation 
assays are the gold standard, but these are difficult to 
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implement and not widely available. Therefore, there is 
a need for alternative methods. 
Here, we describe the use of antigen-microarrays to 
measure antibodies directed against the receptor-
binding spike domain S1 of hCoV- EMC and SARS-
CoV. The most variable immunogenic CoV antigen is 
the amino-terminal S1 subunit of the spike protein, 
which exhibits at most some 30% amino acid iden-
tity between human CoV isolates (data not shown). 
We describe a specific serological tool, distinguishing 
cross-reactivity with the four common hCoVs belonging 
to the same genus as hCoV-EMC and SARS-CoV (genus 
Betacoronavirus, hCoV-OC43, hCoV-HKU1), and to the 
genus Alphacoronavirus (hCoV-NL63 and hCoV-229E). 
Methods
Protein expression
Plasmids encoding the amino-terminal receptor-bind-
ing spike domain S1 of hCoV-EMC and SARS-CoV, fused 
to the Fc part of human IgG, were expressed in HEK-
293T cells, and S1-Fc proteins were purified from the 
culture supernatant by protein A chromatography as 
described [18]. Purified S1-Fc was cleaved by throm-
bin at the S1-Fc junction. Soluble S1 was subsequently 
purified by gel-filtration chromatography and concen-
trated using Amicon Ultra-0.5 filter (Merck, Darmstadt, 
Germany). 
Preparation and testing of microarrays
Purified hCoV-EMC S1 and SARS-CoV S1 were spotted 
in quadruplicate in two drops of 333 pL each in a two-
fold dilution series ranging from 1:2 to 1:8 (starting at 
200 µg/mL for undiluted antigen) on 16-pad nitrocellu-
lose-coated slides (Fast Slides, Maine Manufacturing, 
Grand Blanc, US) using a non-contact Piezorray spotter 
(PerkinElmer, Waltham, US) as described earlier [19]. 
Slides were pre-treated with Blotto blocking buffer to 
avoid non-specific binding as described [19]. Dilutions 
of serum in Blotto containing 0.1 % Surfact-Amps 20 
(Thermo Fisher Scientific Inc. Breda, the Netherlands) 
were transferred in a volume of 90 µL to the slides 
and incubated for 1 h at 37 ºC in a moist chamber. 
Sera tested for the presence of IgM were treated with 
GullSORB (Meridian Bioscience Inc., Cincinnati, US) to 
eliminate rheumatoid factor and immune IgG, which 
can interfere with IgM assays. Upon washing, goat 
anti-human IgG (Fc-fragment specific) or IgM (Fc5µ-
fragment specific) conjugated with DyLight649 fluores-
cent dye (Jackson Immuno Research, West Grove, US) 
was incubated for 1 h at 37 ºC in a moist chamber. After 
washing with buffer and water, the slides were dried. 
Fluorescence signals were quantified by a ScanArray 
Gx Plus microarray scanner (PerkinElmer) using an 
adaptive circle (diameter 80–200 µm) with a saturated 
signal at 65,535. Median spot fluorescence foreground 
intensity (background subtracted) was determined 
using ScanArray Express vs 4.0 software. 
Sera
For validation experiments the following serum sam-
ples were used. All sera were stored at -20 ºC or  80 ºC 
prior to testing. 
•	Anonymised serum samples from 72 persons ranging 
in age from 0 year to 95 years sampled during 2008. 
These sera had been sent to the Dutch National 
Institute for Public Health and the Environment 
(RIVM) for routine Bordetella pertussis serology and 
thus represented a cohort biased towards patients 
with non-influenza-like respiratory symptoms. 
Anonymised use of serum from RIVM was covered 
by the rules of the code of conduct for proper use 
of human tissue of the Dutch Federation of Medical 
Scientific Associations. 
•	Anonymised serum samples of 10 children, ages 
ranging from 9 to 14 months, known to be positive 
for antibodies to one of the four common hCoVs, as 
determined by comparative ELISA using N antigen 
at a dilution factor of 1:200 [20,21]. Samples were 
obtained in 2001, were stored at -80°C and were cho-
sen from this age group because antibodies at this 
age most likely result from single exposures [21]. Two 
hCoV-HKU1, two hCoV-OC43, three hCoV-229E and 
three hCoV-NL63 IgG positive sera were used. 
•	Three anonymised hCoV-OC43-positive sera (includ-
ing one paired sample) from patients with virologi-
cally (PCR) and serologically (IgG IFA) confirmed 
infection, and one hCoV-OC43 IgG positive serum as 
described in [22]. 
•	Serum samples from two cynomolgus macaques 
infected with hCoV-EMC (virus stock obtained as 
described [23]) taken at 28 days post infection, 
including a pre-infection serum. 
•	A serum sample from a rabbit immunised with hCoV-
EMC S1 taken 28 days post immunisation, including a 
pre-immunisation serum. 
•	One serum sample from an hCoV-EMC infected 
patient who was treated for SARI in a hospital in 
Essen, Germany taken at day 20 after onset of illness. 
This serum had an IgG titre of 1:10,000 and an IgM 
titre of 1:1,000 as determined by IFA on cells infected 
with hCoV-EMC and an IgM and IgG titre of >1:320 as 
determined by IFA on cells expressing recombinant S 
protein [10,22,23]. 
•	Convalescent serum samples from two SARS-CoV 
infected patients. Serum SARS-1 was taken 3.5 years 
after disease. It had an IgG titre of 1:160 and no IgM 
titre as determined by IFA on cells expressing recom-
binant S protein [22]. Serum SARS-2 was taken 36 
days after onset of illness with an IgG titre of 1:1,000 
in IFA and 1:1,600 in ELISA. No IgM titre was found 
by IFA (personal communication, M. Niedrig, March 
2013). 
•	Convalescent serum samples of three patients with 
severe respiratory complaints who had travelled to 
SA, Dubai and Dubai/Qatar within 10 days before 
onset of illness, and therefore had been tested to 
exclude hCoV-EMC by RT-PCR, as recommended by 
WHO. 
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All human sera were collected in accordance with the 
ethical principles set out in the declaration of Helsinki; 
Macaque and rabbit sera were collected in compliance 
with Dutch laws on animal handling and welfare.
Results
Testing antigen quality
The amino-terminal receptor-binding spike domains S1 
of hCoV-EMC and SARS-CoV were spotted in serial dilu-
tions (1:2–1:8) on nitrocellulose slides and incubated 
with two-fold serial dilutions (1:20–1:640) of sera from 
hCoV-EMC-infected macaques, a rabbit immunised with 
hCoV-EMC S1, or a SARS-CoV-infected patient. All sera 
showed high-level IgG reactivity with their homolo-
gous S1 antigen, while only background reactivity was 
observed with the heterologous antigen. Pre-immune 
serum of macaque and rabbit were non-reactive (Table). 
Based on these observations it was concluded that the 
antigens as printed on the array slides were intact and 
in the proper conformation for immuno-reactivity with 
homologous antibodies. 
Validation of protein array
To analyse the specificity of the microarray for detec-
tion of hCoV-EMC and SARS-CoV IgM and IgG anti-
bodies, the reactivity of a cohort of human sera 
submitted to the RIVM for whooping cough diagnostics 
was tested. The cohort consisted of 72 sera of non-
exposed patients, ranging from 0–95 years of age. This 
cohort represents the putative cross-reacting potential 
in the Dutch population, where previous studies have 
shown high seroprevalences for one or more of the 
four common hCoVs [20,21]. The sera were tested for 
IgM and IgG reactivity with the hCoV-EMC and SARS-
CoV antigens at dilutions 1:20 and 1:40 (Table, Figure 
1). The observed reactivity was low. Based on these 
results an arbitrary cut-off was set at 5,000 for IgM and 
at 10,000 for IgG measurements.
The specificity of the microarray was confirmed using 
serum samples from children with known recent expo-
sure and antibody responses to one of the four com-
mon hCoVs, including the betacoronaviruses OC43 and 
HKU1. Sera were tested at dilutions 1:20 and 1:160, 
with one serum for each hCoV tested in a two-fold dilu-
tion series of 1:20 to 1:640. None of the 14 sera showed 
reactivity above background, for either IgG or IgM, with 
the hCoV-EMC and SARS-CoV antigens (Table, Figures 1 
and 2). 
Subsequently, the array was tested with a single serum 
sample taken in the third week of illness of a patient 
infected with hCoV-EMC [22], and convalescent serum 
samples of two patients taken during the SARS-CoV 
epidemic. The serum of the hCoV-EMC patient showed 
a clear positive reactivity for IgG with EMC S1 in the 
dilution range from 1:20 to 1: 20,480, declining only 
at dilutions 1:5,120 and higher. The IgM reactivity of 
the hCoV-EMC serum with EMC antigen was saturated 
in the dilution range from 1:20 to 1:80, with declining, 
but clearly positive, levels of reactivity at higher dilu-
tions. No reactivity was observed with SARS antigen 
for either IgG or IgM. 
Table 
Summary results of the validation of the hCoV-EMC and SARS-CoV S1 protein microarray (n=94)
hCoV-EMC Aga SARS-CoV Aga
Sera Number IgG IgM IgG IgM
Human
Population sera human 72 Negative Negative Negative Negative
hCoV-OC43 human 6 Negative Negative Negative Negative
hCoV-229E human 3 Negative Negative Negative Negative
hCoV-NL63 human 3 Negative Negative Negative Negative
hCoV-HKU1 human 2 Negative Negative Negative Negative
hCoV-EMC human 1 Positive Positive Negative Negative
SARS-CoV human 2 Negative Negative Positive Negative
Animal
Pre-immunisation rabbit 1 Negative Not tested Negative Not tested
hCoV-EMC post-immunisation rabbit 1 Positive Not tested Negative Not tested
Pre-infection macaque 1 Negative Not tested Negative Not tested
hCoV-EMC post-infection macaque 2 Positive Not tested Negative Not tested
Ag: S1 antigen. 
a Reactivity was scored based on the arbitrary set cut-off. 
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Figure 1
IgM and IgG reactivity of two-step serially diluted sera with hCoV-EMC S1- and SARS-CoV S1-spotted microarrays (n=89)
Sera: 72 population sera 1:20 diluted (panel A (IgM) and E (IgG)), hCoV-EMC (panel B (IgM) and F (IgG)), SARS-CoV serum SARS-1 (panel C (IgM) 
and G (IgG)) and hCoV-OC43 (panel D (IgM) and H (IgG)). Panels C and G are representative for all SARS-CoV sera tested (n=2). Panels D and 
H are representative for all common hCoV sera tested (n=14). 
X-axes denote serum numbers (panel A and E) or serum dilutions: two-step serial dilutions, staring dilution 1:20. 
Y-axes denote the measured median spot foreground fluorescence intensities.
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The two SARS-CoV sera SARS-1 and SARS-2 gave a 
clear positive reaction with the SARS antigen for IgG 
at dilutions from 1:20 to 1:80 and from 1:20 to 1:160, 
respectively, with no reactivity for IgM using the cho-
sen cut-off. No reactivity was observed with the EMC 
antigen (Table, Figures 1 and 2). 
Serological diagnosis
Convalescent sera from three patients with severe res-
piratory symptoms and a travel history to the Middle 
East were tested using the newly developed microar-
ray. None of the patients showed positive reactivity for 
IgM or IgG with EMC-S1. 
Discussion
We present a protein microarray-based serological test 
for the confirmation of hCoV-EMC and SARS-CoV infec-
tions. A major obstacle in the development of detection 
tools for novel, emerging viruses is the availability of 
sufficient, well-defined negative and positive sera for 
the assessment of the specificity and sensitivity of the 
assays. Nevertheless, results so far suggest that our 
microarray is highly specific for the detection of IgM 
and IgG antibodies against these emerging hCoVs, with 
no false-positive reactivity in 72 population sera and 
14 sera known to be positive for one of the four widely 
circulating hCoVs -OC43, -HKU1, -229E and -NL63. 
Samples with a high titre were preferred for assay vali-
dation, but the exact titres of the antibodies against 
the common hCoVs in the latter validation cohort were 
not known. 
However, previous studies from the Netherlands have 
found that by the age of 30 months, more than 50% 
of children seroconverted to one or more of the alpha- 
(hCoV-NL63, hCoV-229E) or betacoronaviruses (hCoV-
OC43, hCoV-HKU1), and seropositivity reached 100% 
by 10 years of age for alphacoronaviruses [20,21]. The 
seroprevalence for betacoronaviruses was not specifi-
cally tested in the Netherlands, but found to be 91% in 
adults in the United States [24]. Therefore, the absence 
of false-positives in our population samples is strong 
evidence for the specificity of the method. IgG and IgM 
antibodies to hCoV-EMC and IgG to SARS-CoV were 
clearly detectable in positive patient sera. However, 
due to the small number of available positive patient 
sera, determination of the sensitivity of the assay in 
relation to viral load, clinical manifestation and phase 
Figure 2
Representative pictures of the protein microarray analysis of convalescent sera from patients infected with the six known 
hCoVs (n=17)
SARS Ag  EMC Ag      SARS Ag       EMC Ag  
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EMC  
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Ag: antigen.
Vertically from top to bottom: Incubation with sera containing antibodies to SARS-CoV, hCoV-EMC, hCoV-HKU1, hCoV-OC43, hCoV-229E or 
hCoV-NL63. 
IgG (left panel) and IgM (right panel) reactivity of the six sera to SARS-CoV and hCoV-EMC S1 protein (SARS Ag and EMC Ag respectively). 
Colours reflect median spot intensity as shown in the legend on the right. 
Antigens spotted in quadruplicate with dilution factor 1:2; sera dilution factor 1:20.
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of infection requires further investigation. For this 
essential clinical validation, international sharing of 
positive sera by (national) laboratories in possession 
of such sera is a prerequisite. 
Currently, WHO and ECDC recommend the collection of 
paired serum samples, preferably from the acute and 
convalescent phase, of all cases under investigation, 
as serological testing might be necessary to confirm 
infection when clinical presentation and epidemiology 
suggest an infection with hCoV-EMC despite negative 
PCR results [2,12]. In addition, serology is needed for 
contact investigations and source tracking. A two-
staged serological approach is recommended, which 
proved effective in a contact investigation of an hCoV-
EMC infection treated in Germany. It uses IFA with 
virus-infected cells for screening, and as second-stage 
recombinant spike- and nucleocapsid-transfected cells 
and virus neutralisation tests [22]. Our protein microar-
ray enables specific, one-stage, high-throughput test-
ing, with the benefit of minimal sample requirement. 
This technique can use dried blood spots for testing, 
which greatly facilitates shipping of samples. 
The serological assay presented here is available and 
of great value for human and animal population screen-
ing, both of which are necessary to gain insight in the 
epidemiology of the novel hCoV. The array format can 
be modified to identify primary and intermediate ani-
mal reservoirs by simple adaptation of the conjugate 
used to visualise reactivity on the array (data not 
shown). Our assay is available to aid diagnosis in indi-
vidual patients, for confirmatory testing of positive 
tests and for (large-scale) contact studies.
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